KAREN FIELDING: Open Payments
NPI 1437388014 · DANVERS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,964 in 100 payments from 15 companies in 2025. Trend: 2023 $1,533 · 2024 $1,803 · 2025 $1,964
Food & beverage: $1,964
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $542 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $251 |
| Janssen Biotech, Inc. | 12 | $197 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $160 |
| Madrigal Pharmaceuticals | 6 | $144 |
| Celltrion USA Inc. | 8 | $143 |
| Phathom Pharmaceuticals, Inc. | 5 | $116 |
| GENZYME CORPORATION | 5 | $112 |
| Regeneron Healthcare Solutions, Inc. | 4 | $70 |
| PFIZER INC. | 3 | $65 |
Products named: ENTYVIO, TREMFYA, CREON, DUPIXENT, REZDIFFRA, VEGZELMA, RINVOQ, VOQUEZNA.
Industry payments across MA — which companies pay providers there.
